This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Georges M. Gharabawi, MD; Cynthia A. Bossie, PhD; Ramy Mahmoud, MD, MPH; Carla M. Canuso, MD; Robert A. Lasser, MD; Ibrahim Turkoz, MS; and Andrew Greenspan, MD

Published: January 16, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Regarding a trial recently reported in the Journal1 comparing risperidone and ziprasidone in the short-term treatment of schizophrenia, we concur with the authors that "more head-to-head comparisons of antipsychotics are needed to discern the relative efficacy and safety profiles of these compounds."(p1624) This trial furthers progress toward good comparative research in part by illustrating some methodological limitations applicable to future research. The article contains some broad conclusions that do not appear to be supported by the reported data.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: